RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

The study showed diabetic patients taking GLP-1 drugs, such as semaglutide and tirzepatide, faced significantly lower risks of 30-day readmission, wound re-opening and hematoma after surgery, compared ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

Medspas are leading the charge in offering GLP-1 treatments, with 60% of medspas in the U.S. now providing these services, compared to 35% of aesthetic physician offices. Average spend per patient ...

Highmark Health President and CEO David Holmberg discussed the uncertainties facing the insurance industry, including the ...

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

Popular medications, such as Ozempic, Mounjaro and Wegovy, are known as GLP-1 agonists as they mimic the natural GLP-1s ...